Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications

被引:144
作者
Czarnowicki, Tali [1 ,2 ]
Krueger, James G. [1 ,2 ]
Guttman-Yassky, Emma [1 ,3 ]
机构
[1] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA
[2] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA
[3] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
关键词
Atopic dermatitis; Microbiome; Immune dysregulation; Skin barrier; Proactive treatment; Residual disease genomic profile; Intrinsic atopic dermatitis; Extrinsic atopic dermatitis; STAPHYLOCOCCUS-AUREUS COLONIZATION; THYMIC STROMAL LYMPHOPOIETIN; EPIDERMAL LANGERHANS CELLS; GENE-EXPRESSION; T-CELLS; BETA-DEFENSIN-2; EXPRESSION; FLUTICASONE PROPIONATE; FILAGGRIN MUTATIONS; PROACTIVE THERAPY; DENDRITIC CELLS;
D O I
10.1016/j.jaip.2014.03.006
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Atopic dermatitis is the most common chronic inflammatory skin disease. Its pathogenesis combines barrier defects, immune dysregulation, and increased skin infections; however, the relative contribution of each of these components is yet to be determined. Uninvolved atopic dermatitis skin also displays broad immune and barrier abnormalities, which highlights a role for proactive treatment strategy. The residual disease genomic profile that accompanies clinical resolution provides further support for proactive treatment approaches. Although intrinsic and extrinsic atopic dermatitis subtypes share a common clinical phenotype, they show some important differences in their Th22/ Th17 cytokine profile, which opens the door for personalized specific therapeutics for each disease category. (C) 2014 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:371 / 379
页数:9
相关论文
共 137 条
[1]   Staphylococcal-mediated worsening of atopic dermatitis: many players involved [J].
Agner, T. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (06) :1147-1147
[2]   Immunological differences between intrinsic and extrinsic types of atopic dermatitis [J].
Akdis, CA ;
Akdis, M .
CLINICAL AND EXPERIMENTAL ALLERGY, 2003, 33 (12) :1618-1621
[3]  
Akdis M, 1997, J IMMUNOL, V159, P4611
[4]   Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis [J].
Altrichter, Sabine ;
Kriehuber, Ernst ;
Moser, Julia ;
Valenta, Rudolf ;
Kopp, Tamara ;
Stingl, Georg .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (09) :2232-2239
[5]   Anti-IgE - emerging opportunities for Omalizumab [J].
Babu, K. Suresh ;
Polosa, Riccardo ;
Morjaria, Jaymin B. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) :765-777
[6]   An update on the genetics of atopic dermatitis: Scratching the surface in 2009 [J].
Barnes, Kathleen C. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (01) :16-29
[7]  
Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, p[16, e1]
[8]   Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review [J].
Bath-Hextall, F. J. ;
Birnie, A. J. ;
Ravenscroft, J. C. ;
Williams, H. C. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (01) :12-26
[9]   Toward a major risk factor for atopic eczema:: Meta-analysis of filaggrin polymorphism data [J].
Baurecht, Hansjoerg ;
Irvine, Alan D. ;
Novak, Natalija ;
Illig, Thomas ;
Buehler, Bettina ;
Ring, Johannes ;
Wagenpfeil, Stefan ;
Weidinger, Stephan .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (06) :1406-1412
[10]   A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis [J].
Behshad, Ramona ;
Cooper, Kevin D. ;
Korman, Neil J. .
ARCHIVES OF DERMATOLOGY, 2008, 144 (01) :84-88